A rare case of catastrophic antiphospholipid syndrome triggered by estrogen‐containing oral contraceptives in a patient with double heterozygous factor V Leiden and prothrombin G20210A mutations
- 23 February 2021
- journal article
- editorial
- Published by Wiley in American Journal of Hematology
- Vol. 97 (2), 239-242
- https://doi.org/10.1002/ajh.26138
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS RegistryAutoimmunity Reviews, 2016
- Catastrophic antiphospholipid syndrome: a clinical review2014
- Catastrophic antiphospholipid syndrome (CAPS)Best Practice & Research Clinical Rheumatology, 2012
- Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraceptionBlood, 2011
- Hormonal Contraception and Thrombotic Risk: A Multidisciplinary ApproachPEDIATRICS, 2011
- Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210ACirculation, 2010
- The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control studyBMJ, 2009
- Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the “CAPS Registry”Journal of Autoimmunity, 2009
- Relapsing Catastrophic Antiphospholipid Syndrome: Report of Three CasesSeminars in Arthritis and Rheumatism, 2008
- Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutationThe Lancet, 1994